Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia.

Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia.
复制标题

严重肢体缺血患者肌内 phVEGF165 基因转移后慢性缺血性神经病变的改善。

DOI:
--
复制
发表时间:
2001
影响因子:
--
通讯作者:
D. H. Weinberg
D. H. Weinberg
中科院分区:
--
文献类型:
--
作者:
D. Simovic;J. Isner;A. Ropper;A. Pieczek;D. H. Weinberg

文献摘要

参考文献

被引文献

相似文献

客观的
OBJECTIVE To investigate the effects of vascular endothelial growth factor gene therapy on ischemic neuropathy in patients with critical limb ischemia. DESIGN An open-label, dose-escalating trial. Patients with angiographically proven critical leg ischemia received injections of phVEGF(165) human plasmid in the muscles of the ischemic limb. Testing before treatment and at 3 and 6 months included (1) symptom severity score, (2) clinical examination score, and (3) electrophysiologic studies. Clinical and electrophysiologic examiners were masked to each other's findings. SETTING A tertiary care referral hospital and a major teaching affiliate of Tufts University School of Medicine, Boston, Mass. RESULTS Of 29 consecutive patients enrolled, 17 (19 limbs) completed the 6 months of study. Six patients had diabetes. Compared with baseline studies, treated patients had significant clinical improvements in the symptom score (P<.01), sensory examination score (P<.01), total examination score (P =.01), peroneal motor amplitude (P =.03), and quantitative vibration threshold (P =.04). Improvement in the vascular ankle-brachial index in treated legs (P<.01) corresponded to improvement in neuropathy in the same limb. Neurologic improvement was seen in 4 of 6 patients with diabetes who completed the study. No clinical, electrophysiologic, or vascular improvements were observed in untreated legs. CONCLUSIONS Ischemic neuropathy might be a reversible condition, and therapeutic angiogenesis might be an effective treatment. The presence of diabetes does not preclude a response to this therapy.
DOI: 10.1172/jci1560
发表时间: 1998-06-01
影响因子: 15.9
作者:
Murohara, T;Asahara, T;Isner, JM
通讯作者: Isner, JM
DOI: 10.1161/01.cir.99.1.111
发表时间: 1999-01-12
期刊: CIRCULATION
影响因子: 37.8
作者:
Rivard, A;Fabre, JE;Isner, JM
通讯作者: Isner, JM
DOI: --
发表时间: 1995
期刊: The American journal of pathology.
影响因子: --
作者:
Takeshita,S;Rossow,ST;Kearney,M;Zheng,LP;Bauters,C;Bunting,S;Ferrara,N;Symes,JF;Isner,JM
通讯作者: Isner,JM
DOI: 10.1161/01.cir.94.12.3281
发表时间: 1996-12
期刊: Circulation
影响因子: 37.8
作者:
Y. Tsurumi;S. Takeshita;Dongfen Chen;M. Kearney;S. Rossow;J. Passeri;J. Horowitz;J. Symes;J. Isner
通讯作者: Y. Tsurumi;S. Takeshita;Dongfen Chen;M. Kearney;S. Rossow;J. Passeri;J. Horowitz;J. Symes;J. Isner
DOI: 10.1172/jci117018
发表时间: 1994-02-01
影响因子: 15.9
作者:
TAKESHITA, S;ZHENG, LP;ISNER, JM
通讯作者: ISNER, JM